Middle East & North Africa | Prevalence of HIV, female (% ages 15-24)
Prevalence of HIV, female is the percentage of females who are infected with HIV. Youth rates are as a percentage of the relevant age group. Limitations and exceptions: The limited availability of data on health status is a major constraint in assessing the health situation in developing countries. Surveillance data are lacking for many major public health concerns. Estimates of prevalence and incidence are available for some diseases but are often unreliable and incomplete. National health authorities differ widely in capacity and willingness to collect or report information. Statistical concept and methodology: HIV prevalence rates reflect the rate of HIV infection in each country's population. Low national prevalence rates can be misleading, however. They often disguise epidemics that are initially concentrated in certain localities or population groups and threaten to spill over into the wider population. In many developing countries most new infections occur in young adults, with young women especially vulnerable. Data on HIV are from the Joint United Nations Programme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions for estimating the data and better coordination with countries have resulted in improved estimates of HIV and AIDS. The models, which are routinely updated, track the course of HIV epidemics and their impact, making full use of information in HIV prevalence trends from surveillance data as well as survey data. The models take into account reduced infectivity among people receiving antiretroviral therapy (which is having a larger impact on HIV prevalence and allowing HIV-positive people to live longer) and allow for changes in urbanization over time in generalized epidemics. The estimates include plausibility bounds, which reflect the certainty associated with each of the estimates.
Publisher
The World Bank
Origin
Middle East & North Africa
Records
63
Source
Middle East & North Africa | Prevalence of HIV, female (% ages 15-24)
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
0.1 1990
0.1 1991
0.10029941 1992
0.10086604 1993
0.10144048 1994
0.10225822 1995
0.10335924 1996
0.1045032 1997
0.1056799 1998
0.10623728 1999
0.10646542 2000
0.10585939 2001
0.10528509 2002
0.1041198 2003
0.10323223 2004
0.1023992 2005
0.1018701 2006
0.10134995 2007
0.10110025 2008
0.10084729 2009
0.10058115 2010
0.10060073 2011
0.10062269 2012
0.1006458 2013
0.10033475 2014
0.10034563 2015
0.10035533 2016
0.10036427 2017
0.10037152 2018
0.10037596 2019
0.10037864 2020
0.10037936 2021
2022
Middle East & North Africa | Prevalence of HIV, female (% ages 15-24)
Prevalence of HIV, female is the percentage of females who are infected with HIV. Youth rates are as a percentage of the relevant age group. Limitations and exceptions: The limited availability of data on health status is a major constraint in assessing the health situation in developing countries. Surveillance data are lacking for many major public health concerns. Estimates of prevalence and incidence are available for some diseases but are often unreliable and incomplete. National health authorities differ widely in capacity and willingness to collect or report information. Statistical concept and methodology: HIV prevalence rates reflect the rate of HIV infection in each country's population. Low national prevalence rates can be misleading, however. They often disguise epidemics that are initially concentrated in certain localities or population groups and threaten to spill over into the wider population. In many developing countries most new infections occur in young adults, with young women especially vulnerable. Data on HIV are from the Joint United Nations Programme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions for estimating the data and better coordination with countries have resulted in improved estimates of HIV and AIDS. The models, which are routinely updated, track the course of HIV epidemics and their impact, making full use of information in HIV prevalence trends from surveillance data as well as survey data. The models take into account reduced infectivity among people receiving antiretroviral therapy (which is having a larger impact on HIV prevalence and allowing HIV-positive people to live longer) and allow for changes in urbanization over time in generalized epidemics. The estimates include plausibility bounds, which reflect the certainty associated with each of the estimates.
Publisher
The World Bank
Origin
Middle East & North Africa
Records
63
Source